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Background: Travel to countries with high or inter-
mediate hepatitis A virus (HAV) endemicity is a risk 
factor for infection in residents of countries with low 
HAV endemicity.  Aim:  The objective of this study was 
to estimate the risk for hepatitis A among European 
travellers using surveillance and travel denominator 
data.  Methods:  We retrieved hepatitis A surveillance 
data from 13 European Union (EU)/ European Economic 
Area (EEA) countries with comprehensive surveil-
lance systems and travel denominator data from the 
Statistical Office of the European Union. A travel-asso-
ciated case of hepatitis A was defined as any case 
reported as imported. Results: From 2009 to 2015, the 
13 countries reported 18,839 confirmed cases of hepa-
titis A, of which 5,233 (27.8%) were travel-associated. 
Of these, 39.8% were among children younger than 15 
years. The overall risk associated with travel abroad 
decreased over the period at an annual rate of 3.7% 
(95% confidence interval (CI): 0.7–2.7) from 0.70 cases 
per million nights in 2009 to 0.51 in 2015. The high-
est risk was observed in travellers to Africa (2.11 cases 
per million nights). Cases more likely to be reported 
as travel-associated were male and of younger age 
(< 25 years). Conclusion: Travel is still a major risk fac-
tor for HAV infection in the EU/EEA, although the risk 
of infection may have slightly decreased in recent 
years. Children younger than 15 years accounted for a 
large proportion of cases and should be prioritised for 
vaccination.
Background
Hepatitis A is one of the most common causes of food-
borne infection worldwide [1]. The disease spreads 
by faecal-oral transmission either by consumption 
of contaminated food or person-to-person contact 
[2]. Although the global burden of hepatitis A has 
decreased in the past 20 years [3], the World Health 
Organisation (WHO) still defines most of the world’s 
low- and middle-income countries as experiencing 
high or intermediate hepatitis A virus (HAV) endemicity 
[4]. In Europe, the incidence of hepatitis A decreased 
substantially [5,6] and most countries in the European 
Union (EU)/ European Economic Area (EEA) currently 
experience low or very low HAV endemicity [7]. In such 
populations with an increasing proportion of suscep-
tible individuals, travel is an important risk factor for 
infection [2,6]. European travellers to countries with 
high HAV endemicity are often infected when consum-
ing contaminated food items or drinks during travel 
[8,9]. A similar epidemiology is observed in other high-
income countries such as the United States (US) where 
ca 40% of all hepatitis A cases are travel-associated 
[10].
The WHO and most EU/EEA countries recommend HAV 
vaccination to European travellers visiting countries 
with intermediate or high endemicity [11]. Nevertheless, 
findings from a recent survey among overseas travel-
lers from France, Germany, Italy, Spain, and the United 
Kingdom (UK) suggested a moderate vaccine coverage 
against HAV with only half of the occasional travellers 
visiting endemic countries vaccinated [12].
A population-based study carried out in Sweden 
showed that the highest risk was associated with 
travel to East Africa, the Middle East and the Indian 
subcontinent [13]. The highest risk was found among 
young children visiting friends and relatives, as in 
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another study carried out in the Netherlands [14]. It is 
difficult to compare findings from studies performed at 
national level for several reasons, including different 
data sources, populations and methodologies. Pooling 
data from several countries improves statistical power 
and allows for broader generalisation of the findings.
The objectives of this study were to describe the epi-
demiology of travel-associated hepatitis A, to estimate 
the risk for hepatitis A among travellers from EU/EEA 
countries and to identify groups at higher risk to help 
target and prioritise interventions.
Methods
Hepatitis A data
Surveillance of hepatitis A at the EU/EEA level is car-
ried out by the Food- and Waterborne Diseases and 
Zoonoses Network (FWD-Net) under the coordina-
tion of the European Centre for Disease Prevention 
and Control (ECDC). The network comprises all 28 
EU Member States, Iceland and Norway, which annu-
ally report hepatitis A cases among their residents to 
the European Surveillance System (TESSy) database 
hosted by ECDC. Cases are reported with a set of vari-
ables including age, sex, importation status and prob-
able country of infection.
A travel-associated case of hepatitis A is defined as 
any case reported as imported, i.e. infected following 
exposure outside the reporting country during a time 
compatible with the incubation period. For the pur-
pose of this analysis, we included data from 13 EU/
EEA countries (Austria, Denmark, Estonia, Finland, 
France, Germany, Greece, Hungary, Luxembourg, 
Malta, the Netherlands, Norway and Portugal) for the 
years 2009 to 2015. These countries (total population: 
223 million) have comprehensive and compulsory 
surveillance systems for hepatitis A and reported case-
based hepatitis A data for at least 80% of cases with 
known importation status during the study period. We 
chose this threshold arbitrarily to obtain reliable esti-
mates for the proportion of travel-associated cases. 
In Denmark, Luxembourg and Portugal, surveillance 
was based on physician reporting only, whereas it was 
based on both laboratory and physician reporting in 
other countries [15]. The participating countries follow 
WHO recommendations as most EU/EEA countries do, 
i.e. they vaccinate groups at increased risk of infection. 
In addition, Greece has since 2008 provided universal 
vaccination to all children older than 12 months [7].
We included cases with known importation status 
who met the EU case definition criteria for a confirmed 
case of hepatitis A, i.e. any person meeting the clini-
cal criteria and the laboratory criteria (detection of HAV 
nucleic acid in serum or stool or HAV-specific antibody 
response or detection of HAV antigen in stool) [16].
Travel data
We obtained travel denominator data for the period 
from 2009 to 2015 from the Statistical Office of the 
European Union (Eurostat) [17]. We used the total 
number of nights spent, by destination country, which 
includes all nights that EU/EEA residents, aged 15 or 
older, spent in a collective accommodation establish-
ment or in private tourist accommodation for personal 
Figure 1
Risk of travel-associated cases of hepatitis A by million 
nights, 11 EU/EEA countriesa, 2009−2015 (n = 4,705)
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a Austria, Denmark, Estonia, Finland, France, Germany, Greece, 
Hungary, Luxembourg, Malta, Portugal.
Figure 2
Seasonality of travel-associated cases of hepatitis A, 13 
EU/EEA countriesa, 2009−2015 (n = 5,218)
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a Austria, Denmark, Estonia, Finland, France, Germany, Greece, 
Hungary, Luxembourg, Malta, the Netherlands, Norway, 
Portugal.
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or professional purposes. In most countries, this infor-
mation is collected through household surveys. The 
collection of data should conform to the specifications 
described in the  Methodological manual for tourism 
statistics  [18]. A country may apply weighting proce-
dures according to the sampling design used. Since 
travel nights were not available for all combinations of 
the different countries of residence with the different 
destination countries for all years, we estimated the 
total number of nights from the mean number of nights 
for the available years multiplied by 7 (study period of 
7 years).
Analysis
We compared travel-associated cases of hepatitis A 
with non-travel-associated cases for main charac-
teristics. We defined the risk for travel-associated 
hepatitis A as the rate of travel-associated cases per 
million nights spent in a given destination (region or 
continent) by all travellers from the reporting country. 
We excluded France from the analysis by destination 
because information on the probable country of infec-
tion was not available. We also excluded Estonia and 
Norway for this part of the analysis because travel data 
were missing for some destinations. We considered 
five main regions as destinations (Africa, America, 
Asia, Europe and Oceania). Following Eurostat group-
ing, we divided America further into (i) North America 
and (ii) Central and South America (including Mexico). 
In Europe, we distinguished EU countries from other 
European countries (including Turkey). We calculated 
95% confidence intervals (CI) for risk, assuming a 
Poisson distribution. To assess the trend in the annual 
risk for travel-associated hepatitis A over time, we esti-
mated the annual rate of change and its 95% CI using 
a log-linear regression of risk for travel-associated hep-
atitis A associated with overseas travel in the period 
from 2009 to 2015.
We compared continuous variables across strata by 
Mann–Whitney U test. We compared categorical vari-
ables using the chi-squared or Fisher’s exact tests with 
a significance level of less than 0.05.
To further characterise travel-associated hepatitis A, 
we assessed the association of age and sex with the 
cases’ travel status (dependent variable) in a logis-
tic regression analysis and estimated adjusted odds 
ratios (OR) and 95% CI.
Ethics statement
Hepatitis A is part of the 52 communicable diseases for 
which ECDC routinely collects, analyses and dissemi-
nates surveillance data as stated by the Article 3 of its 
founding regulation. TESSy data are pseudonymised 
Table 1
Main characteristics of reported cases of hepatitis A by travel status, and adjusted predictors of travel-associated hepatitis A, 
13 EU/EEA countriesa, 2009−2015 (n = 18,839)
Characteristic
Non-travel-associated 
cases Travel-associated cases
Univariate logistic 
regression
Multivariable logistic 
regressionb
n % n % OR (95% CI) OR (95% CI)
Total 13,606 100 5,233 100 Not included Not included
Sex
Male 7,356 54.1 2,907 55.6 1.06 (0.99–1.13) 1.10 (1.02–1.18)
Female 6,240 45.9 2,325 44.4 1 1
Unknownc 10 Not included 1 Not included Not included Not included
Age group (years)
< 5 712 5.2 483 9.2 2.05 (1.79–2.34) 1.59 (1.38–1.83)
5–14 3,230 23.7 1,600 30.6 1.50 (1.37–1.63) 1.38 (1.25–1.52)
15–24 2,206 16.2 958 18.3 1.31 (1.19–1.45) 1.45 (1.30–1.62)
25–44 3,714 27.3 1,230 23.5 1 1
45–64 2,481 18.2 803 15.3 0.98 (0.88–1.08) 0.80 (0.72–0.89)
≥ 65 1,262 9.3 159 3.0 0.38 (0.32–0.45) 0.24 (0.20–0.29)
Unknownc 1 Not included 0 Not included Not included Not included
Outcome
Alive 8,791 99.9 2,433 99.8 Not included Not included
Dead 8 0.1 4 0.2 Not included Not included
Unknownc 4,807 Not included 2,796 Not included Not included Not included
CI: confidence interval; OR: odds ratio.
a Austria, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Luxembourg, Malta, the Netherlands, Norway, Portugal.
b Adjusted for year and reporting country with France as reference.
c Percentages exclude the unknown.
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and processed for public interest in the area of public 
health. Informed consent was not required.
Results
In the period from 2009 to 2015, the 13 participating 
countries reported 20,556 confirmed cases of hepa-
titis A, of which 18,839 (91.6%) had known travel 
status. Of these 18,839, 5,233 (27.8%) were travel-
associated (Table 1). Four countries had proportions 
of travel-associated cases below 25%: Hungary (1.1%), 
Greece (11.3%), Estonia (17.0%) and Malta (22.7%). Of 
the 5,233 travel-associated cases, 2,581 (49.3%) were 
reported with available information on the probable 
country of infection. When excluding France, informa-
tion on probable country of infection was available for 
2,581 (94.8%) of 2,723 travel-associated cases.
Demographics
Of the 5,232 travel-associated cases with known sex, 
2,907 (55.6%) were male giving a male-to-female ratio 
of 1.3:1 (Table 1). There was a non-significant differ-
ence between the proportion of travel-associated 
cases in male compared with female cases (28.3% vs 
27.2%; p = 0.07). The male-to-female ratio was lower in 
younger and older age groups (1.1:1 below 15 years and 
1.0:1 at 65 years and above), peaking at 1.5:1 for those 
25–44 years of age. Of the 5,233 travel-associated 
cases, 2,083 (39.8%) were children younger than 15 
years. The proportion of travel-associated cases in that 
age group was below 30% in Malta (17.0%), Hungary 
(17.0%) and Estonia (4.4%). Of the 2,437 travel-associ-
ated case with known outcome, four died (0.2%).
Trend and seasonality
Over the study period, the average annual number of 
travel-associated cases was 748 (range: 637–867). 
The highest numbers of travel-associated cases were 
observed in 2009 and 2013 with 867 and 795 cases, 
respectively. Annual numbers of nights spent abroad 
were available for all countries and all years except 
for the Netherlands (only years 2012−15) and Norway 
(only years 2009−11). Between 2009 and 2015, for the 
11 countries with available data on nights spent for all 
years, the overall annual risk for hepatitis A associated 
with overseas travel was 0.58 cases per million nights. 
The logarithmic trendline showed a decrease at an 
annual rate of 3.7% (95% CI: 0.7–2.7) from 0.70 cases 
per million nights in 2009 to 0.51 in 2015 (Figure 1).
 
Of the 5,218 travel-associated cases with known month 
of reporting, 2,016 (38.6%) were reported between 
August and October, including 1,181 (22.6%) in the 
month of September alone (Figure 2). Of the 2,078 
travel-associated cases younger than 15 years for whom 
the month of reporting was known, 1,235 (59.4%) were 
reported between August and October.
Travel patterns
From 2009 to 2015, residents from the 13 participat-
ing countries spent ca 9.6 billion nights abroad (Table 
2). The most visited regions were Europe (78.4% of 
all nights spent, including Turkey), America (8.5%) 
and Asia (7.4%). Travellers only spent 4.6% of their 
nights in Africa and 1.1% in Oceania. Travellers from 
France and Portugal spent a larger proportion (13.3% 
Table 2
Number of nights spent on overseas trips, by reporting country and world region of destination, 13 EU/EEA countriesa, 
2009−2015 (n = 9,638 million)
Country
Nights spent on oversea trips
n (million)
Distribution by destination (%)
Africa America Asia Europe Oceania
Austria 469 3.8 6.6 6.8 81.9 0.9
Denmark 364 3.6 8.9 9.6 76.8 1.1
Estonia 52 3.1 18.5 7.1 71.3 No data
Finland 313 2.6 7.6 11.3 77.0 1.5
France 1,500 13.3 12.8 8.9 63.6 1.4
Germany 4,971 5.1 8.6 7.3 77.9 1.2
Greece 59 3.0 6.3 5.5 85.0 0.2
Hungary 187 2.1 9.8 4.6 82.4 1.1
Luxembourg 73 4.5 6.1 4.2 84.9 0.3
Malta 16 5.8 4.3 4.9 82.2 2.8
The Netherlandsb 1,180 3.9 8.3 6.5 80.3 1.1
Norwayc 369 4.2 8.2 9.6 77.0 1.0
Portugal 85 9.6 12.4 3.6 73.8 0.7
Total 9,638 4.6 8.5 7.4 78.4 1.1
a Austria, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Luxembourg, Malta, the Netherlands, Norway, Portugal.
b Number of nights only available for 2012−2015. The figure used is an estimate based on the average for available years.
c Number of nights only available for 2009−2011. The figure used is an estimate based on the average for available years.
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and 9.6%, respectively) of their nights in Africa com-
pared with those from other countries. Travellers from 
Denmark, Finland and Norway spent 9.6% or more of 
their nights in Asia.
Within Europe, most nights were spent in the EU 
(84.5%). This proportion was below 80% for travel-
lers from Estonia (71.5%) and Greece (58.4%). Overall, 
63.8% of the nights spent in America were in North 
America.
Nine of the 13 countries included had a risk between 
0.20 and 0.46 cases per million nights. Travellers from 
France (1.67 cases per million nights), Greece (1.03), 
Estonia (0.87) and Portugal (0.73) had a higher risk 
(Table 3).
Of the 2,581 cases reported by 12 countries with infor-
mation on probable country of infection (data from 
France excluded), 2,416 (93.6%) resided in the 10 
countries for which travel data were available for all 
destinations (travel data for Estonia and Norway were 
not available for all destinations). Among these 2,416 
cases, the overall risk for travel-associated hepatitis A 
was 0.31 cases per million nights spent overseas. The 
highest risks were observed with travel to Africa (2.11 
cases per million nights) and Asia (1.25) (Table 4).
Travel to Egypt, Turkey and Morocco accounted for 
30.9% of all travel-associated cases reported with 
information on probable country of infection (Table 5). 
While most cases returning from Turkey and Morocco 
were reported in the period from August to October 
(64.2% and 62.6%, respectively), 47.7% of cases 
returning from Egypt were reported between November 
and February. Of note, of the 69 cases associated with 
travel to Italy, 24 were reported in 2013. The propor-
tion of cases younger than 15 years was above 70% for 
cases reported with a travel to Afghanistan, Ethiopia, 
Iraq or Pakistan and below 10% for cases who travelled 
to France, Greece, Spain and Thailand. The proportion 
of cases younger than 15 years was noticeably low in 
travellers to Egypt (14.7%) and India (17.9%) com-
pared with neighbouring countries such as Lebanon 
(45.0%) or Pakistan (73.6%). In the EU, this proportion 
was higher in travellers to Romania (29.4%), Bulgaria 
(22.6%) and Italy (20.3%) compared with other EU 
countries.
Multivariable analysis
Male travellers were more likely than female travel-
lers to have acquired their infection abroad (adjusted 
OR = 1.10; 95% CI: 1.02–1.18) (Table 1), and younger 
cases were more likely to be travel-associated than 
older cases. Compared with those aged 25–44 years, 
children younger than 5 years were 60% more likely to 
be reported with a probable infection abroad (adjusted 
OR = 1.59; 95% CI: 1.38–1.83).
Discussion 
Principal findings
In the participating European countries, 27.8% of 
reported hepatitis A cases were travel-associated. Both 
Table 3
Number of travel-associated cases of hepatitis A, number of nights spent and risk by reporting country, 13 EU/EEA 
countries, 2009−2015 (n = 5,233)
Country
Travel-associated cases Nights 
 
(million)
Cases/million nights (95% CI)
n % % <15 years
Austria 96 1.8 36.5 469 0.21 (0.17–0.25)
Denmark 167 3.2 41.9 364 0.46 (0.39–0.53)
Estonia 45 0.9 4.4 52 0.87 (0.64–1.16)
Finland 78 1.5 38.5 313 0.25 (0.20–0.31)
France 2,510 48.0 43.1 1,500 1.67 (1.61–1.74)
Germany 1,619 30.9 37.1 4,971 0.33 (0.31–0.34)
Greece 61 1.2 34.4 59 1.03 (0.79–1.33)
Hungary 47 0.9 17.0 187 0.25 (0.19–0.33)
Luxembourg 15 0.3 33.3 73 0.20 (0.11–0.34)
Malta 5 0.1 20.0 16 0.32 (0.10–0.74)
The Netherlands a 400 7.6 40.8 1,180 0.34 (0.31–0.37)
Norway b 128 2.4 34.4 369 0.35 (0.29–0.41)
Portugal 62 1.2 33.9 85 0.73 (0.56–0.94)
Total 5,233 100 39.8 9,638 0.54 (0.53–0.56)
CI: confidence interval.
a Number of nights only available for 2012−2015. The figure used is an estimate based on the average for available years.
b Number of nights only available for 2009−2011. The figure used is an estimate based on the average for available years.
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this proportion and the number of travel-associated 
cases were stable over the study period. However, the 
risk for travel-associated hepatitis A per nights spent 
overseas decreased. This is consistent with decreases 
reported from the Netherlands [14] and Denmark in 
the 2000s [19]. The large number of cases reported 
in 2013 may have been related to a large multistate 
food-borne outbreak with more than 1,500 cases in 
the EU/EEA [20]. It is possible that other outbreaks 
also played a role in the fluctuations observed in these 
data. More than 60% of all travel-associated hepati-
tis A cases were associated with travel to Africa and 
Asia, although these destinations accounted for less 
than 15% of all nights spent overseas. These findings 
are hardly surprising because these two continents 
host most countries with high endemicity [4]. However, 
these estimates at continental level may mask impor-
tant disparities. Some European countries are also at 
moderate to high risk for HAV infection.
Age and seasonality appeared to be related to specific 
destinations. Pakistan was associated with a large pro-
portion of cases younger than 15 years, most of whom 
were reported between August and October. These 
children were most probably accompanying their par-
ents during the summer vacation. Conversely, Egypt, 
India and most European countries were associated 
with more cases among adults and a less pronounced 
seasonality. This may be suggestive of leisure travel 
without children or business travel which is year-round 
for some destinations.
Interestingly, most countries of residency included 
in the analysis had comparable travel patterns and 
estimated risks, suggesting that some of these findings 
could be generalised to other European countries not 
included in this study. The higher risk observed in trav-
ellers from France and Portugal, compared with other 
countries, could be partly driven by a higher proportion 
of nights spent in Africa, a destination where travellers 
are at high risk of acquiring hepatitis A. Similarly, trav-
ellers from Estonia and Greece had a high proportion 
of nights spent in Eastern Europe and Turkey, which 
are destinations of higher risk compared with Western 
Europe [4].
Strengths and weaknesses of the study
This study included more than 5,000 travel-associ-
ated hepatitis A cases reported by 13 countries. These 
countries account for more than 40% of the EU/EEA 
population. Our findings provide a good picture of the 
epidemiology of travel-associated hepatitis A in Europe 
in recent years. However, this study had some limita-
tions. Firstly, a large proportion of mild non-specific 
or entirely asymptomatic hepatitis A cases, espe-
cially among children, were probably not captured by 
the surveillance systems. In addition, given the long 
incubation period of hepatitis A and the possibility 
of a case having visited several countries, countries 
may have misclassified some of their cases, and it is 
challenging to assess the effect of this type of error 
in our analysis. Secondly, information on the prob-
able country of infection was not available for cases 
reported by France, which accounted for nearly half of 
travel-associated cases reported over the study period. 
Thirdly, we excluded countries with low coverage of 
their surveillance system (e.g. Italy) or low complete-
ness of the travel status (e.g. the UK). Fourthly, nights 
Table 4
Number of travel-associated cases of hepatitis A, number of nights spent and risk by travel destination, 10 EU/EEA 
countriesa, 2009−2015 (n = 2,416)
Region
Travel-associated cases Nights 
 
(million, estimate 2009−15b)
Cases/million nights (95% CI)
n % % <15 years
Total (all regions) 2,416 100 39.8 7,794 100 0.31 (0.30–0.32)
Africa 753 31.2 33.3 357 4.6 2.11 (1.96–2.27)
America
North America 10 0.4 0.0 412 5.3 0.02 (0.01–0.04)
Central and South Americac 106 4.4 14.2 228 2.9 0.46 (0.38–0.56)
Asia 705 29.2 50.4 564 7.2 1.25 (1.16–1.35)
Europe
EU 28 427 17.7 13.6 5,150 66.1 0.08 (0.07–0.09)
Other European countriesd 410 17.0 56.8 995 12.8 0.41 (0.37–0.45)
Oceania 5 0.2 0.0 88 1.1 0.06 (0.02–0.13)
CI: confidence interval.
a Austria, Denmark, Finland, Germany, Greece, Hungary, Luxembourg, Malta, the Netherlands and Portugal.
b The number of travel-associated cases was aggregated for the period 2009 to 2015, but travel nights were not available for all combinations 
of the different countries of residence with the different destination countries for all years. We therefore estimated the total number of 
nights from the mean number of nights for the available years multiplied by 7 (study period of 7 years).
c Including Mexico.
d Including Turkey.
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spent by EU/EEA residents younger than 15 years were 
not available. Although children are unlikely to travel 
without their parents, we may have overestimated the 
risk in destinations with a large proportion of cases in 
children (e.g. Asia). Unfortunately, travel denomina-
tor data at country level were not available for most 
destination countries outside Europe. Lastly, there 
were limitations related to the travel data. These data 
were collected mostly via household survey [17] which 
is prone to recall bias. In addition, number of nights 
spent in destinations with few travellers (e.g. Oceania) 
can show high variations over time [17]. However, we 
think that overall, these data were reliable with little 
variation over the study period for most destinations 
considered in the analysis.
Information on travel purpose and probable route of 
infection were not available. Some authors have rec-
ommended recording the travel purpose in order to 
inform public health strategies [21]. For example, peo-
ple visiting friends and relatives are at a higher risk of 
acquiring travel-associated infection [22-24]. However, 
visiting friends and relatives may not be the sole pur-
pose of the journey and the classical definition of vis-
iting friends and relatives has been challenged [25]. 
Information on the probable route of infection may also 
be useful for informing prevention strategies as hepa-
titis A infection can also be sexually transmitted and 
men who have sex with men are a known risk group 
[26].
Comparison with other studies
Our risk estimate (0.54 cases per million nights) is 
higher than data reported by Askling et al. who esti-
mated a risk of travel-associated hepatitis A of 0.61 
cases per 100,000 travel months (i.e. 0.20 cases per 
million nights) among Swedish travellers [13]. Our over-
all estimate was probably driven by France, a country 
whose travellers spent more nights in Africa and were 
shown to be less likely to be vaccinated compared with 
other European travellers [12]. As in our study, Askling 
at al. found a higher risk associated with travel to 
some parts of Africa and Asia. The proportion of travel-
associated cases in our study (ca 30%) was lower than 
in the US (ca 40%) [10]. However, this overall propor-
tion masks important disparities across countries and 
was heavily influenced by countries reporting many 
locally acquired cases such as Hungary. Alongside 
Romania and Slovakia, Hungary was one of the few 
EU/EEA countries with a notification rate above 10 
cases per 100,000 population in 2014 [15]. In the late 
1990s, routine hepatitis A vaccination of children was 
Table 5
Top destinations for travel-associated hepatitis A cases, 12 EU/EEA countriesa, 2009−2015 (n = 2,581)
Rank Destination country Region
Travel-associated cases
n % % <15 years
1 Turkey Other European countries 318 12.3 61.3
2 Egypt Africa 279 10.8 14.7
3 Morocco Africa 200 7.7 52.0
4 Pakistan Asia 140 5.4 73.6
5 Afghanistan Asia 130 5.0 80.0
6 India Asia 106 4.1 17.9
7 Syria Asia 92 3.6 52.2
8 Spain EU 28 86 3.3 3.5
9 Italy EU 28 69 2.7 20.3
10 Lebanon Asia 60 2.3 45.0
11 Namibia Africa 59 2.3 15.3
12 Romania EU 28 51 2.0 29.4
13 Iraq Asia 42 1.6 73.8
14 Bulgaria EU 28 31 1.2 22.6
14 France EU 28 31 1.2 6.5
16 Ethiopia Africa 29 1.1 79.3
17 Peru Central and South America 28 1.1 25.0
18 Croatia Africa 26 1.0 26.9
19 Philippines Asia 25 1.0 24.0
20 Greece EU 28 24 0.9 8.3
20 Thailand Asia 24 0.9 8.3
Other destinations 731 28.3 25.2
Total 2,581 100 36.9
a Austria, Denmark, Estonia, Finland, Germany, Greece, Hungary, Luxembourg, Malta, the Netherlands, Norway and Portugal.
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implemented in those states in the US with the high-
est incidence, leading to decreases in incidence among 
younger age groups [27]. It is possible that this strat-
egy, implemented at local level, had a large impact on 
domestically acquired cases overall by decreasing HAV 
circulation in the US.
The high proportion of infection in children return-
ing from countries less frequented by tourists (e.g. 
Afghanistan, Iraq or Pakistan) is very suggestive of 
travel to visit friends and relatives or recent immigra-
tion. This would confirm reports from Australia where 
travel-associated infections in children were more fre-
quently associated with visiting friends and relatives 
than in adults [22]. The large number of refugees enter-
ing Europe in 2015 is unlikely to have had any major 
effect on our findings because reports from Germany 
and Greece suggested that hepatitis A cases in this 
population were only observed in late 2015 and 2016 
[28,29].
Possible explanations and implications for 
clinicians and policymakers
During the period from 2009 to 2015, the notification 
rate of hepatitis A cases in the EU/EEA was fairly sta-
ble at ca three cases per 100,000 population, with 
the highest notification rate observed in children 
aged 5–14 years. Our data suggest that the risk of 
travel-associated cases decreased slightly over the 
period. A molecular cluster analysis carried out in the 
Netherlands showed that travelling children were an 
important group for introduction and further trans-
mission of HAV [30]. HAV vaccination, for children of 
families travelling to countries of high or intermediate 
endemicity would probably have a high impact on the 
number of travel-associated hepatitis A cases in Europe 
and consequently on secondary locally acquired cases. 
For example, HAV incidence in children of Moroccan 
or Turkish descent steadily declined after the intro-
duction of targeted HAV vaccination programmes in 
the Netherlands [31]. More generally, hepatitis A vac-
cine is recommended for all non-immune travellers to 
countries of intermediate or high endemicity. Since a 
single dose of hepatitis A vaccine provides high protec-
tion even when given shortly before departure [32], any 
increase in opportunities for vaccination would be ben-
eficial (e.g. vaccination clinics at airports). However, 
the recent vaccine shortages in some European coun-
tries may jeopardise efforts to promote vaccination 
[33]. Studies exploring other factors for not getting 
vaccinated (risk perception, cost etc.) would also help 
design effective public health measures [34].
Conclusion
Travel remains a major risk factor for HAV infection in 
the EU/EEA, although the risk of infection may have 
slightly decreased over recent years. This still repre-
sents a considerable cause of morbidity which could be 
avoided since a safe, effective and affordable vaccine 
is available. Children younger than 15 years account for 
a large proportion of cases and should be prioritised 
for vaccination, particularly when travelling to visit rel-
atives and friends in HAV-endemic countries.
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